4.10.25.2Vertical
Infusion Therapy for Rheumatology
Infusion centers delivering biologic infusions for rheumatologic conditions.
Market snapshot
These figures describe Rheumatology (4.10.25), the segment that Infusion Therapy for Rheumatology sits within. They are not figures for Infusion Therapy for Rheumatology on its own.
FragmentationConsolidatingEstimate
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.
Business model & economics
Revenue model
Office reimbursement plus in-office biologic infusion margin
Key economics
- Recurring revenue
- High
- EBITDA margin
- 18–28% with infusion ancillaries
- Capex intensity
- Low
chronic autoimmune care and infusion
Characteristics
- In-office biologic infusion drives ancillary economics.
- Autoimmune prevalence and biologics growth.
- Rheumatologist shortage and emerging MSO interest.
M&A deal context
Deal activityModerate
Who’s acquiring
- Infusion-focused MSO platforms
- PE-backed rheumatology consolidators
- Multispecialty acquirers
What’s driving deals
- Roll-up for infusion ancillary economics.
- Autoimmune and biologics demand.
- Rheumatologist shortage.
Find Infusion Therapy for Rheumatology acquisition targets
Search Acquisera’s index for companies classified under Infusion Therapy for Rheumatology (4.10.25.2) and build a targeted deal pipeline.
Search companies